G-CON PODs® Selected as Supplier for Clinical and Commercial Manufacturing Facility in Redmond, Washington

G-CON to supply prefabricated modular cGMP manufacturing suites for Just – Evotec Biologics’ first J.POD® facility in North America

G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions announced today that the company will support Just – Evotec Biologics, a wholly-owned Seattle-based company of Evotec SE, with their construction of a late-stage clinical and commercial manufacturing facility for biologics in Redmond, Washington. The news comes shortly after the announcement of the construction of Just – Evotec Biologics’ first J.POD® facility in North America, creating the “Facility of the Future” to provide flexible and modular, larger scale manufacturing of clinical and commercial-stage biologics.

Just – Evotec Biologics’ J.POD® technology features small intensified bioprocessing operations housed inside G-CON cleanroom PODs. G-CON will design and fabricate the PODs for cGMP manufacturing suites that require mobility and reconfigurability to meet current and future needs. The one-of-a-kind cGMP biomanufacturing facility includes six J.PODs® for upstream and downstream processing, totaling 8,825 sq. ft. of cleanroom space using the G-CON POD product. A key feature of the facility is its flexible platform design with the ability to scale out with additional PODs in the future without interrupting existing processes, resulting in zero operational scale-up risks.

The facility is part of Just – Evotec Biologics’ plan to provide flexible, high-quality manufacturing while de-risking drug discovery and development, not only for Just – Evotec Biologics, but also for Evotec’s partners.

“We treasure the partnership with Just – Evotec Biologics, a company supporting the shared vision of highly flexible and readily deployable manufacturing sites,” stated Maik Jornitz, CEO of G-CON.

About G-CON Manufacturing 
G-CON Manufacturing designs, builds and installs prefabricated G-CON POD® cleanrooms. G-CON’s POD portfolio provides cleanrooms in a number of dimensions for a variety of uses, from laboratory environments to personalized medicine and production process platforms. G-CON POD® cleanroom units surpass traditional cleanroom structures in scalability, mobility and the possibility of repurposing the PODs once the production process reaches its lifecycle end. For more information, please visit G-CON’s website at http://www.gconbio.com. Follow us on Twitter at @g_con_pods.

About Just – Evotec Biologics 
Just – Evotec Biologics wholly owned by Evotec SE is a unique platform company that integrates the design, engineering, development, and manufacture of biologics. With deep experience in the fields of protein, process and manufacturing sciences, the Just team came together to solve the scientific and technical hurdles that block access to life-changing protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. Our focus is to create access and value for a global market through scientific and technological innovation. Learn more at http://www.just.bio.

About Evotec SE 
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec


We treasure the partnership with Just – Evotec Biologics, a company supporting the shared vision of highly flexible and readily deployable manufacturing sites.